We are live on ! Find out more
IBB icon

iShares Biotechnology ETF

668 hedge funds and large institutions have $5.09B invested in iShares Biotechnology ETF in 2020 Q1 according to their latest regulatory filings, with 82 funds opening new positions, 175 increasing their positions, 253 reducing their positions, and 116 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more funds holding in top 10

Funds holding in top 10: 1114 (+3)

4.42% less ownership

Funds ownership: 84.16%79.73% (-4.4%)

6% less funds holding

Funds holding: 710668 (-42)

21% less capital invested

Capital invested by funds: $6.41B → $5.09B (-$1.32B)

29% less first-time investments, than exits

New positions opened: 82 | Existing positions closed: 116

31% less repeat investments, than reductions

Existing positions increased: 175 | Existing positions reduced: 253

51% less call options, than puts

Call options by funds: $359M | Put options by funds: $729M

Holders
668
Holders Change
-42
Holders Change %
-5.92%
% of All Funds
14.72%
Holding in Top 10
14
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+27.27%
% of All Funds
0.31%
New
82
Increased
175
Reduced
253
Closed
116
Calls
$359M
Puts
$729M
Net Calls
-$370M
Net Calls Change
+$154M

IBB Hedge Fund Activity: Q1 2020 in Review

668 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2020, worth a combined $5.09B — down 21% from $6.41B a quarter earlier.

Sellers outnumbered buyers: 116 funds closed out of IBB and 82 opened new positions — a net loss of 34 holders — while 253 trimmed existing stakes and 175 added.

The largest buyer was JP Morgan Chase, adding an estimated $142M. The largest seller was Citigroup, cutting an estimated $352M.

  • 668 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2020, down from 710 in Q4 2019.
  • Funds reported $5.09B of iShares Biotechnology ETF stock for Q1 2020, down 21% quarter-over-quarter.
  • 82 funds opened new iShares Biotechnology ETF positions in Q1 2020 and 116 closed out, a net change of -34 holders.
  • The largest iShares Biotechnology ETF buyer in Q1 2020 was JP Morgan Chase, an estimated $142M added.
  • The largest iShares Biotechnology ETF seller in Q1 2020 was Citigroup, an estimated $352M sold.

Based on aggregated 13F filings for Q1 2020.